Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

COPENHAGEN (Reuters) -Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S.

Novo Nordisk says the decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...